List view / Grid view
An analysis reveals that in comparison to other inflammatory diseases such as cytokine-release syndrome (CRS) and sepsis, the levels of cytokines in severely ill COVID-19 patients is low.
![Wasp on a wooden platform [Credit: University of Pennsylvania].](https://www.drugtargetreview.com/wp-content/uploads/Vespula-lewisii-wasp-750x500.jpg)
![Wasp on a wooden platform [Credit: University of Pennsylvania].](https://www.drugtargetreview.com/wp-content/uploads/Vespula-lewisii-wasp-e1602594547599.jpg)
Altering the mastoparan-L (mast-L) peptide found in Vespula lewisii wasp venom, researchers created several novel antimicrobial molecules.
Researchers are utilising computers to aid in their investigations into a COVID-19 treatment. Here, we highlight three studies using simulations, calculations and AI to identify a drug to combat the coronavirus.
Tests have shown that LAL assays produced from L. polyphemus in aquaculture often has a higher activity than lyophilised and preserved LAL from commercial kits.
James Graham from Recce Pharmaceuticals discusses how a new class of synthetic antibiotics could be the key to preventing the spread of antibiotic resistance.
A new monoclonal antibody has been discovered which disassociates bacterial biofilms and stops bacteria from entering into circulation has been tested in mice.
Scientists have used nanotechnology to transform healthy immune cells into a drug with enhanced power to kill bacteria to help the immune system fight sepsis.
Researchers have found that damage to mitochondria due to sepsis may be the cause of muscle weakness in mice.
Isolated components found in the Saussurea controversa plant have antimicrobial and regenerative properties which could lead to a treatment for bone diseases.
A new study has demonstrated the possibility of treating antibiotic-resistant Pseudomonas aeruginosa which causes sepsis in burn patients.
The gut microbiota has been linked to organ damage in patients with sepsis suggesting targeting intestinal microbiota may help patients' recovery.
Researchers have discovered that removing the enzyme, PHLPP1, improves outcomes in a mouse model of sepsis so could be a potential drug target.
Researchers have found a set of genes which helps cells survive during sepsis in mice and could inform potential treatments for the condition.
An inhibitor that stops the action of OGG1 signals, could potentially be used as a treatment for life-threatening Acute Respiratory Distress Syndrome...
Research sheds light on the initial phase of infectious disease and potential for prevention of pneumococcal septicaemia...
